584 results on '"Goudemand J"'
Search Results
2. Coagulation standards in healthy newborns and infants
3. OC 60.5 Response to Desmopressin in Type 2N Von Willebrand’s Disease: A Genotype-Phenotype Analysis on a Cohort of 121 Patients
4. PB0818 Impact of ABO Blood Group Genotype on VWF Level in Carriers of Type 3 von Willebrand Disease from the French von Willebrand Disease Reference Center
5. Characterization of large in-frame von Willebrand factor deletions highlights differing pathogenic mechanisms
6. Safety and pharmacokinetics of subcutaneously administered recombinant activated factor VII (rFVIIa)
7. New findings on inhibitor development: from registries to clinical studies
8. von Willebrand factor variant p.Arg924Gln marks an allele associated with reduced von Willebrand factor and factor VIII levels
9. Validation of a rapid test (VWF-LIA) for the quantitative determination of von Willebrand factor antigen in type 1 von Willebrand disease diagnosis within the European multicenter study MCMDM-1VWD
10. Expression of 14 von Willebrand factor mutations identified in patients with type 1 von Willebrand disease from the MCMDM-1VWD study
11. Factor XI replacement for inherited factor XI deficiency in routine clinical practice: results of the HEMOLEVEN prospective 3-year postmarketing study
12. Early von Willebrand factor degradation upon acute exposure to high shear stress under continuous-flow circulatory assist devices: OR219
13. Determinants of inhibitor development in previously treated hemophilia A patients: OR144
14. Plasma-derived factor VIII products and inhibitor development in previously untreated boys with severe hemophilia A: report of the FranceCoag Network: OR143
15. Type 2N von willebrand disease: one variant but more than one disease: OR024
16. Heterogeneity of von willebrand disease type 3 in a french cohort of 75 patients: OR025
17. Maladie de Willebrand
18. Pharmacokinetics and pharmacodynamics of a new highly secured fibrinogen concentrate
19. Detailed von Willebrand factor multimer analysis in patients with von Willebrand disease in the European study, molecular and clinical markers for the diagnosis and management of type 1 von Willebrand disease (MCMDM‐1VWD)
20. FXI concentrate use and risk of thrombosis
21. Costs and management of patients with hemophilia A in France: the Hemraude study
22. Safety and efficacy of a high-purity plasma derived von Willebrand Factor in patients with von Willebrand disease (VWD) undergoing prophylaxis for joint bleeding: results from a post-marketing study
23. Safety and efficacy of a high-purity plasma-derived von Willebrand Factor in patients with von Willebrand disease (VWD) undergoing prophylaxis for gastrointestinal bleeding: results from a post-marketing study
24. Bleeding symptoms in patients diagnosed as type 3 von willebrand disease: results from 3WINTERS‐IPS, an international and collaborative cross‐sectional study
25. Treatment of severe von Willebrand disease with a high‐purity von Willebrand factor concentrate (Wilfactin®): a prospective study of 50 patients
26. Impact of plasma von Willebrand factor levels in the diagnosis of type 1 von Willebrand disease: results from a multicenter European study (MCMDM‐1VWD)
27. Colonoscopy in patients with haemophilia: the duration of clotting factor coverage must be adjusted to suit the procedure
28. von Willebrand disease patients with associated risk factor(s) of venous thromboembolism: efficacy and safety of a von Willebrand factor product with a low factor VIII content: PB 1.43–1
29. Previously missed mutations in the MCMDM-1VWD type 1 von Willebrand disease study: PA 3.09–4
30. Von Willebrand factor activity determination using new assay principle ristocetin-free for reliable von Willebrand disease diagnosis: PA 1.09–2
31. Type 2N von Willebrand disease (VWD): one variant, two diseases? Analysis of the French cohort: OC 13.6
32. Incidence of large VWF gene deletions and duplications in the French cohort of 1182 patients with von Willebrand disease (VWD): OC 13.2
33. Outcome of acquired haemophilia in France: the prospective SACHA (Surveillance des Auto antiCorps au cours de lʼHémophilie Acquise) registry
34. A quantitative analysis of bleeding symptoms in type 1 von Willebrand disease: results from a multicenter European study (MCMDM‐1 VWD)
35. Linkage analysis in families diagnosed with type 1 von Willebrand disease in the European study, molecular and clinical markers for the diagnosis and management of type 1 VWD
36. Impact of Choice of Treatment for Bleeding Episodes on Inhibitor Outcome in Patients With Mild/Moderate Hemophilia A and Inhibitors
37. French cohort of thirty-seven patients with type 3 von Willebrand disease: Molecular and clinical features: PO-MO-258
38. Analysis of the French cohort of sixty-five patients with type 2N von Willebrand disease identifies distinct molecular/clinical entities: PO-MO-257
39. Obstetric management in von Willebrand disease: Results of a retrospective study over a twenty-one-year period: PO-MO-259
40. Clinical characteristics of patients with von Willebrand disease included in the Francecoag network: PO-MO-237
41. Treatment of von Willebrand disease patients undergoing surgical procedures or deliveries with a von Willebrand factor product devoid of FVIII: Results from five multicentre studies: PO-MO-229
42. Clinical use of a von Willebrand factor with a low FVIII content to control major bleeding episodes in von Willebrand disease patients: Results from prospective multicentre studies: PO-MO-230
43. A new class of mutations in the A3 region of von Willebrand factor inducing multiple functional defects in the protein: FP-TU-04.3-1
44. Rare bleeding disorders in the FranceCoag Network: Circumstances of diagnosis and clinical manifestations in the French population of patients with FXI deficiency under twenty per cent: PO-TU-273
45. Design and evaluation of pedagogic tools in therapeutic patient education for hemophilic patients: the French experience: PO-MO-091
46. FranceCoag Network: A Multidisciplinary Partnership between Patients and Health Professionals: PO-MO-023
47. Clotting factor consumption in hemophilia A and B according to patientsʼ characteristics: Results from the FranceCoag Network: PO-TU-026
48. Age at the first bleeding could be a predictor of hemorrhagic phenotype in patients with severe hemophilia: FP-MO-04.4-2
49. Patientsʼ opinion surveys are necessary to assess the quality of the organization of a health facility: PO-MO-009
50. Validation of the first commercial ELISA for type 2N von Willebrandʼs disease diagnosis
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.